Xebra Brands Ltd
Xebra Brands Ltd. engages in the cultivation, processing, manufacture, design, and delivery of cannabis products in Canada, Europe, and Mexico. It provides cannabis infused beverages, including seltzers, soft drinks, iced teas, lemonades, waters, and energy and sport drinks; and wellness products that include capsules, tinctures, topicals, and intimate oils for personal care. The company offers i… Read more
Xebra Brands Ltd (XBRAF) - Net Assets
Latest net assets as of November 2024: $-206.84K USD
Based on the latest financial reports, Xebra Brands Ltd (XBRAF) has net assets worth $-206.84K USD as of November 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($431.44K) and total liabilities ($638.28K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-206.84K |
| % of Total Assets | -47.94% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 60.84 |
Xebra Brands Ltd - Net Assets Trend (2020–2024)
This chart illustrates how Xebra Brands Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Xebra Brands Ltd (2020–2024)
The table below shows the annual net assets of Xebra Brands Ltd from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-02-29 | $-410.59K | -174.44% |
| 2023-02-28 | $551.58K | -77.44% |
| 2022-02-28 | $2.45 Million | -17.89% |
| 2021-02-28 | $2.98 Million | -34.30% |
| 2020-02-29 | $4.53 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Xebra Brands Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1398435600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (February 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $16.62 Million | % |
| Total Equity | $-154.52K | 100.00% |
Xebra Brands Ltd Competitors by Market Cap
The table below lists competitors of Xebra Brands Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Egyptian Arabian(Themar)Comp. For Securities&Bonds Brok. EAC
EGX:EASB
|
$557.12 |
|
Veltex Corporation
OTCQB:VLXC
|
$559.32 |
|
China Dasheng Biotechnology Company
PINK:CDBT
|
$559.38 |
|
AFRICA EATS LTD (USD)
SEM:EATS
|
$560.06 |
|
PP LONDON SUMATRA (PS9A.SG)
STU:PS9A
|
$555.60 |
|
Murray Income Trust Plc
OTCQB:MRRYF
|
$554.49 |
|
Sassy Gold Corp.
OTCQB:SSYRD
|
$554.43 |
|
YHEGF
PINK:YHEGF
|
$554.28 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Xebra Brands Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 795,670 to -154,518, a change of -950,188 (-119.4%).
- Net loss of 1,957,380 reduced equity.
- Other factors increased equity by 1,007,192.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.96 Million | -1266.77% |
| Other Changes | $1.01 Million | +651.83% |
| Total Change | $- | -119.42% |
Book Value vs Market Value Analysis
This analysis compares Xebra Brands Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-02-29 | $0.18 | $0.06 | x |
| 2021-02-28 | $0.12 | $0.06 | x |
| 2022-02-28 | $0.07 | $0.06 | x |
| 2023-02-28 | $0.02 | $0.06 | x |
| 2024-02-29 | $0.00 | $0.06 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Xebra Brands Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1831.81%
- • Asset Turnover: 0.28x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-173.42%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -61.48% | 0.00% | 0.00x | 1.13x | $-3.24 Million |
| 2021 | -61.97% | 0.00% | 0.00x | 1.20x | $-2.16 Million |
| 2022 | -237.86% | 0.00% | 0.00x | 1.12x | $-6.40 Million |
| 2023 | -505.77% | -2531.80% | 0.12x | 1.66x | $-4.10 Million |
| 2024 | 0.00% | -1831.81% | 0.28x | 0.00x | $-1.94 Million |
Industry Comparison
This section compares Xebra Brands Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Xebra Brands Ltd (XBRAF) | $-206.84K | -61.48% | N/A | $556.66 |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |